The effect of glycoprotein-processing inhibitors on the secretion of glycoproteins by Madin-Darby canine kidney cells.
The effects of various glycoprotein-processing inhibitors on the biosynthesis and secretion of N-linked glycoproteins was examined in cultured Madin-Darby canine kidney (MDCK) cells. Since incorporation of [2-3H]mannose into lipid-linked saccharides and into glycoproteins was much greater in phosphate-buffered saline (PBS) than in serum-supplemented basal medium (BME), most experiments were done in PBS. Castanospermine, an inhibitor of glucosidase I, caused the formation of glycoproteins having mostly Glc3Man7-9(GlcNAc)2 structures; deoxymannojirimycin, an inhibitor of mannosidase I, gave mostly glycoproteins with Man9(GlcNAc)2 structures; swainsonine, an inhibitor of mannosidase II, caused the accumulation of hybrid types of oligosaccharides. Castanospermine and swainsonine, either in PBS or in BME medium, had no effect on the incorporation of [2-3H]mannose or [5,6-3H]leucine into the secreted glycoproteins and, in fact, there was some increase in mannose incorporation in their presence. These inhibitors also did not affect mannose incorporation into cellular glycoproteins nor did they affect the biosynthesis as measured by mannose incorporation into lipid-linked saccharides. On the other hand in PBS medium, deoxymannojirimycin, at 25 micrograms/mL, caused a 75% inhibition in mannose incorporation into secreted glycoproteins, but had no effect on the incorporation of [3H]leucine into the secreted glycoproteins. Since deoxymannojirimycin also strongly inhibited mannose incorporation into lipid-linked oligosaccharides in PBS, the decreased amount of radioactivity in the secreted and cellular glycoproteins may reflect the formation of glycoproteins with fewer than normal numbers of oligosaccharide chains, owing to the low levels of oligosaccharide donor. However, in BME medium, there was only slight inhibition of mannose incorporation into lipid-linked saccharides and into cellular and secreted glycoproteins.
D017485:1-Deoxynojirimycin; D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D002460:Cell Line; D004285:Dogs; D005944:Glucosamine / Q000031:analogs & derivatives / Q000494:pharmacology; D006020:Glycopeptides / Q000032:analysis; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors; D007212:Indolizines; D007668:Kidney; D007700:Kinetics; D008358:Mannose / Q000378:metabolism; D017026:Swainsonine; D054836:Indolizidines
D017485:1-Deoxynojirimycin; D000470:Alkaloids; D005944:Glucosamine; D006020:Glycopeptides; D006023:Glycoproteins; D006026:Glycoside Hydrolases; D007212:Indolizines; D008358:Mannose; D017026:Swainsonine; C037806:castanospermine; D054836:Indolizidines